Jim Cramer says CVS stock is a buy at these levels. Here's why

CVS is identified as a strong performer amidst a struggling healthcare sector, driven by a significant recovery in its Aetna managed care business and robust pharmacy operations capitalizing on competitor weakness. Recent strong financial results, including exceeding estimates and raising its outlook, further validate its operational improvements. Despite a 58% year-to-date stock gain, the stock is considered undervalued, offering a relative safe haven against broader industry headwinds like regulatory uncertainty and rising costs.

Analysis

CVS is demonstrating significant operational resilience and is positioned as a standout performer in a healthcare sector facing broad headwinds. The company's recent quarterly results, which comfortably surpassed earnings and revenue estimates, prompted a raised full-year outlook, marking a sharp reversal from the multiple forecast cuts issued last year. A key driver of this turnaround is the stabilization of its managed care business, Aetna, which was previously a major concern; while medical costs remain elevated, management appears to be executing a durable recovery. Concurrently, the retail pharmacy division is aggressively capturing market share, benefiting directly from the strategic retrenchment and financial distress of its main competitors, including Walgreens' decision to go private and close stores and Rite Aid's recent bankruptcy filing. Despite the stock's substantial 58% year-to-date appreciation, the analysis suggests it remains attractively valued, or "super cheap," on the basis of rising earnings expectations, complemented by a generous dividend yield. This combination of internal operational improvement and a favorable competitive landscape positions CVS as a relative "port in the storm" for investors navigating sector-wide challenges like regulatory uncertainty and potential tariffs.

Key Decisions for Investors

• Given the strong earnings momentum, raised guidance, and significant market share opportunities arising from competitor distress, investors could view CVS as a favorable investment within the lagging healthcare sector.
• The ongoing recovery of the Aetna managed care business is a critical component of the investment thesis, so investors should closely monitor medical cost trends and management's execution in this segment.
• While the stock is presented as undervalued, its 58% year-to-date gain warrants consideration, and investors should weigh the company-specific strengths against persistent sector-wide headwinds, including regulatory and tariff concerns.